Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
89.4M
-
Number of holders
-
207
-
Total 13F shares, excl. options
-
101M
-
Shares change
-
+2.5M
-
Total reported value, excl. options
-
$1.49B
-
Value change
-
+$13M
-
Put/Call ratio
-
0.23
-
Number of buys
-
115
-
Number of sells
-
-114
-
Price
-
$14.80
Significant Holders of Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) as of Q2 2025
272 filings reported holding TVTX - Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share as of Q2 2025.
Travere Therapeutics, Inc. - Common Stock, par value $0.0001 per share (TVTX) has 207 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 101M shares
.
Largest 10 shareholders include JANUS HENDERSON GROUP PLC (9.54M shares), ARMISTICE CAPITAL, LLC (8.88M shares), BlackRock, Inc. (8.17M shares), VANGUARD GROUP INC (5.99M shares), MACQUARIE GROUP LTD (5.1M shares), STATE STREET CORP (3.48M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.78M shares), RENAISSANCE TECHNOLOGIES LLC (2.5M shares), EMERALD ADVISERS, LLC (2.09M shares), and GEODE CAPITAL MANAGEMENT, LLC (2M shares).
This table shows the top 207 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.